Early prediction of nonresponders to treatment with interferon alpha-2b and ribavirin in patients with chronic hepatitis C

Canadian Journal of Gastroenterology

Volumn 17, Issue 8, 2003, Pages 483-487

  Liu, Louis W C ^a   Tomlinson, George ^b   Mazzulli, Tony ^c   Murray, Alison ^d   Heathcote, Jenny ^e  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d GLAXOSMITHKLINE   (United Kingdom)

^e TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Hepatitis C virus; Interferon; Nonresponders; Prediction; Ribavirin; Treatment response

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGE; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; SEX; TIME; VIRUS LOAD;

EID: 0142180166     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2003/351816     Document Type: Article

References (29)

1. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome. Semin Liver Dis 2000;20:17-35.
2. Canadian Association for the Study of the Liver. Canadian consensus conference on the management of viral hepatitis. Can J Gastroenterol 2000;14(Suppl B):5B-20B.
3. Booth JC, O'Grady J, Neuberger J. Clinical guidelines on the management of hepatitis C. Gut 2001;49(Suppl 1):11-21.
4. McHutchison JG, Gordon SC, Schiff ER, et al, for the Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
5. Poynard T, McHutchison J, Goodman Z, et al, for the ALGOVIRC Project Group. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology 2000;31:211-8.
6. Heathcote J. Antiviral therapy for patients with chronic hepatitis C. Semin Liver Dis 2000;20:185-99.
7. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001;358:958-65.
8. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
9. Bodenheimer HC Jr, Lindsay KL, Davis GL, et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial. Hepatology 1997;26:473-7.
10. Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis 1999;19(Suppl 1):67-75.
11. McHutchison JG, Shad JA, Gordon SC, et al. Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy. J Viral Hepat 2001;8:414-20.
12. Brouwer JT, Hansen BE, Niesters HG, et al. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. J Hepatol 1999;30:192-8.
13. Neumann AU, Dahari H, Conrad A, Pianko S, McHutchison JG. Early prediction and mechanism of the ribavirin/IFN-alpha dual therapy effect on chronic hepatitis C virus infection. Hepatology 1999;30:309A. (Abst)
14. Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002;36(Suppl 1):S145-51.
15. Saldanha J, Lelie N, Heath A, for the WHO Collaborative Study Group. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. Vox Sang 1999;76:149-58.
16. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-93.
17. McHutchison J, Blatt L, Sedghi-Vaziri A, et al. Is there an optimal time to measure quantitative HCV RNA to predict non-response following interferon treatment for chronic HCV infection? J Hepatol 1998;29:362-8.
18. Wiley TE, Briedi L, Lam N, et al. Early HCV RNA values after interferon predict response. Dig Dis Sci 1998;43:2169-72.
19. Lee SC, Antony A, Lee N, et al. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: Calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Microbiol 2000;38:4171-9.
20. Trepo C. Genotype and viral load as prognostic indicators in the treatment of hepatitis C. J Viral Hepat 2000;7:250-7.
21. Civeira MP, Prieto J. Early predictors of response to treatment in patients with chronic hepatitis C. J Hepatol 1999;31(Suppl 1):237-43.
22. Kaserer K, Fiedler R, Steindl P, et al. Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C. Histopathology 1998;32:454-61.
23. Jessner W, Gschwantler M, Steindl-Munda P, et al. Primary interferon resistance and treatment response in chronic hepatitis C infection: A pilot study. Lancet 2001;358:1241-2.
24. Shiffman ML, Hofmann CM, Sterling RK, et al. A randomized, controlled trial to determine whether continued ribavirin monotherapy in hepatitis C virus-infected patients who responded to interferon-ribavirin combination therapy will enhance sustained virologic response. J Infect Dis 2001;184:405-9.
25. Shindo M, Hamada K, Oda Y, et al. Long-term follow-up study of sustained biochemical responders with interferon therapy. Hepatology 2001;33:1299-302.
26. Fontana RJ, Moyer CA, Sonnad S, et al. Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C. Am J Gastroenterol 2001;96:170-8.
27. McHutchison JG, Ware JE Jr, Bayliss MS, et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001;34:140-7.
28. Yoshida H, Shiratori Y, Moríyama M, et al, for the Inhibition of Hepatocarcinogenesis by Interferon Therapy Study Group. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999;131:174-81.
29. Buti M, Sanchez-Avila F, Lurie Y, et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology 2002;35:930-6.